Literature DB >> 27520774

Alzheimer's disease-associated TREM2 variants exhibit either decreased or increased ligand-dependent activation.

Wilbur Song1, Basavaraj Hooli2, Kristina Mullin2, Sheng Chih Jin3, Marina Cella1, Tyler K Ulland1, Yaming Wang1, Rudolph E Tanzi4, Marco Colonna5.   

Abstract

INTRODUCTION: TREM2 is a lipid-sensing activating receptor on microglia known to be important for Alzheimer's disease (AD), but whether it plays a beneficial or detrimental role in disease pathogenesis is controversial.
METHODS: We analyzed AD risk of TREM2 variants in the NIMH AD Genetics Initiative Study and AD Sequencing Project. We compared each variant's risk and functional impact by a reporter assay. Finally, we analyzed expression of TREM2 on human monocytes.
RESULTS: We provide more evidence for increased AD risk associated with several TREM2 variants, and show that these variants decreased or markedly increased binding to TREM2 ligands. We identify HDL and LDL as novel TREM2 ligands. We also show that TREM2 expression in human monocytes is minimal compared to monocyte-derived dendritic cells. DISCUSSION: Our results suggest that TREM2 signaling helps protect against AD but can cause harm in excess, supporting the idea that proper TREM2 function is important to counteract disease progression.
Copyright © 2016 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; HDL; LDL; Lipoprotein; Microglia; Monocyte; TREM2

Mesh:

Substances:

Year:  2016        PMID: 27520774      PMCID: PMC5299056          DOI: 10.1016/j.jalz.2016.07.004

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  21 in total

1.  Increased expression of TREM2 in peripheral blood of Alzheimer's disease patients.

Authors:  Nan Hu; Meng-Shan Tan; Jin-Tai Yu; Lei Sun; Lin Tan; Ying-Li Wang; Teng Jiang; Lan Tan
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

2.  TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis.

Authors:  Gernot Kleinberger; Yoshinori Yamanishi; Marc Suárez-Calvet; Eva Czirr; Ebba Lohmann; Elise Cuyvers; Hanne Struyfs; Nadine Pettkus; Andrea Wenninger-Weinzierl; Fargol Mazaheri; Sabina Tahirovic; Alberto Lleó; Daniel Alcolea; Juan Fortea; Michael Willem; Sven Lammich; José L Molinuevo; Raquel Sánchez-Valle; Anna Antonell; Alfredo Ramirez; Michael T Heneka; Kristel Sleegers; Julie van der Zee; Jean-Jacques Martin; Sebastiaan Engelborghs; Asli Demirtas-Tatlidede; Henrik Zetterberg; Christine Van Broeckhoven; Hakan Gurvit; Tony Wyss-Coray; John Hardy; Marco Colonna; Christian Haass
Journal:  Sci Transl Med       Date:  2014-07-02       Impact factor: 17.956

Review 3.  Innate immunity in Alzheimer's disease.

Authors:  Michael T Heneka; Douglas T Golenbock; Eicke Latz
Journal:  Nat Immunol       Date:  2015-03       Impact factor: 25.606

4.  The Triggering Receptor Expressed on Myeloid Cells 2 Binds Apolipoprotein E.

Authors:  Charles C Bailey; Lindsey B DeVaux; Michael Farzan
Journal:  J Biol Chem       Date:  2015-09-15       Impact factor: 5.157

5.  Variant of TREM2 associated with the risk of Alzheimer's disease.

Authors:  Thorlakur Jonsson; Hreinn Stefansson; Stacy Steinberg; Ingileif Jonsdottir; Palmi V Jonsson; Jon Snaedal; Sigurbjorn Bjornsson; Johanna Huttenlocher; Allan I Levey; James J Lah; Dan Rujescu; Harald Hampel; Ina Giegling; Ole A Andreassen; Knut Engedal; Ingun Ulstein; Srdjan Djurovic; Carla Ibrahim-Verbaas; Albert Hofman; M Arfan Ikram; Cornelia M van Duijn; Unnur Thorsteinsdottir; Augustine Kong; Kari Stefansson
Journal:  N Engl J Med       Date:  2012-11-14       Impact factor: 91.245

6.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.

Authors:  W J Strittmatter; A M Saunders; D Schmechel; M Pericak-Vance; J Enghild; G S Salvesen; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

7.  Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE.

Authors:  Lars Bertram; Christoph Lange; Kristina Mullin; Michele Parkinson; Monica Hsiao; Meghan F Hogan; Brit M M Schjeide; Basavaraj Hooli; Jason Divito; Iuliana Ionita; Hongyu Jiang; Nan Laird; Thomas Moscarillo; Kari L Ohlsen; Kathryn Elliott; Xin Wang; Diane Hu-Lince; Marie Ryder; Amy Murphy; Steven L Wagner; Deborah Blacker; K David Becker; Rudolph E Tanzi
Journal:  Am J Hum Genet       Date:  2008-10-30       Impact factor: 11.025

8.  TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model.

Authors:  Yaming Wang; Marina Cella; Kaitlin Mallinson; Jason D Ulrich; Katherine L Young; Michelle L Robinette; Susan Gilfillan; Gokul M Krishnan; Shwetha Sudhakar; Bernd H Zinselmeyer; David M Holtzman; John R Cirrito; Marco Colonna
Journal:  Cell       Date:  2015-02-26       Impact factor: 41.582

9.  TREM2 variants in Alzheimer's disease.

Authors:  Rita Guerreiro; Aleksandra Wojtas; Jose Bras; Minerva Carrasquillo; Ekaterina Rogaeva; Elisa Majounie; Carlos Cruchaga; Celeste Sassi; John S K Kauwe; Steven Younkin; Lilinaz Hazrati; John Collinge; Jennifer Pocock; Tammaryn Lashley; Julie Williams; Jean-Charles Lambert; Philippe Amouyel; Alison Goate; Rosa Rademakers; Kevin Morgan; John Powell; Peter St George-Hyslop; Andrew Singleton; John Hardy
Journal:  N Engl J Med       Date:  2012-11-14       Impact factor: 91.245

10.  Impaired differentiation of osteoclasts in TREM-2-deficient individuals.

Authors:  Marina Cella; Cecilia Buonsanti; Carey Strader; Takayuki Kondo; Andrea Salmaggi; Marco Colonna
Journal:  J Exp Med       Date:  2003-08-11       Impact factor: 14.307

View more
  75 in total

Review 1.  Triggering receptor expressed on myeloid cells 2 (TREM2): a potential therapeutic target for Alzheimer disease?

Authors:  Yuetiva Deming; Zeran Li; Bruno A Benitez; Carlos Cruchaga
Journal:  Expert Opin Ther Targets       Date:  2018-06-20       Impact factor: 6.902

2.  Impact of TREM2 risk variants on brain region-specific immune activation and plaque microenvironment in Alzheimer's disease patient brain samples.

Authors:  Stefan Prokop; Kelly R Miller; Sergio R Labra; Rose M Pitkin; Kevt'her Hoxha; Sneha Narasimhan; Lakshmi Changolkar; Alyssa Rosenbloom; Virginia M-Y Lee; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2019-07-26       Impact factor: 17.088

3.  Curcumin restores innate immune Alzheimer's disease risk gene expression to ameliorate Alzheimer pathogenesis.

Authors:  B Teter; T Morihara; G P Lim; T Chu; M R Jones; X Zuo; R M Paul; S A Frautschy; G M Cole
Journal:  Neurobiol Dis       Date:  2019-04-02       Impact factor: 5.996

4.  Alzheimer disease: TREM-2 signalling and Alzheimer disease - striking the right balance.

Authors:  Heather Wood
Journal:  Nat Rev Neurol       Date:  2016-08-26       Impact factor: 42.937

5.  Quinoline-Pyrazole Scaffold as a Novel Ligand of Galectin-3 and Suppressor of TREM2 Signaling.

Authors:  Moustafa Gabr; Ashfaq Ur Rehman; Hai-Feng Chen
Journal:  ACS Med Chem Lett       Date:  2020-08-11       Impact factor: 4.345

6.  TREM2-activating antibodies abrogate the negative pleiotropic effects of the Alzheimer's disease variant Trem2R47H on murine myeloid cell function.

Authors:  Qingwen Cheng; Jean Danao; Santosh Talreja; Paul Wen; Jun Yin; Ning Sun; Chi-Ming Li; Danny Chui; David Tran; Samir Koirala; Hang Chen; Ian N Foltz; Songli Wang; Shilpa Sambashivan
Journal:  J Biol Chem       Date:  2018-03-29       Impact factor: 5.157

7.  A split-luciferase complementation, real-time reporting assay enables monitoring of the disease-associated transmembrane protein TREM2 in live cells.

Authors:  Megan M Varnum; Kevin A Clayton; Asuka Yoshii-Kitahara; Grant Yonemoto; Lacin Koro; Seiko Ikezu; Tsuneya Ikezu
Journal:  J Biol Chem       Date:  2017-05-10       Impact factor: 5.157

Review 8.  Microglia Function in the Central Nervous System During Health and Neurodegeneration.

Authors:  Marco Colonna; Oleg Butovsky
Journal:  Annu Rev Immunol       Date:  2017-02-09       Impact factor: 28.527

Review 9.  TREM2-Ligand Interactions in Health and Disease.

Authors:  Daniel L Kober; Tom J Brett
Journal:  J Mol Biol       Date:  2017-04-19       Impact factor: 5.469

Review 10.  Reassessment of Pioglitazone for Alzheimer's Disease.

Authors:  Ann M Saunders; Daniel K Burns; William Kirby Gottschalk
Journal:  Front Neurosci       Date:  2021-06-16       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.